Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00392509 · ClinicalTrials.gov registry record · Phase 1
ALD-301 for Critical Limb Ischemia, Randomized Trial
A Phase 1 study of Peripheral Arterial Disease and Peripheral Vascular Disease, sponsored by Aldagen.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
- 5
- Study locations
NCT00392509: Completed Phase 1 study of Peripheral Arterial Disease and Peripheral Vascular Disease, sponsored by Aldagen.
NCT00392509 is a Phase 1 study of Peripheral Arterial Disease and Peripheral Vascular Disease that has completed, run by Aldagen. The registered enrollment target is 20 participants, below the 4,206-participant average among 79 other Peripheral Arterial Disease trials with a reported enrollment target (100% lower). The trial reports 5 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00392509, a Phase 1 study of Peripheral Arterial Disease and Peripheral Vascular Disease, has completed, sponsored by Aldagen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
- 5
- Study locations
Study Summary
This study will treat patients with such severe lower leg ischemia or vascular compromise that they have pain at rest. The goal is to compare treatment of the patient's painful disorder by injecting cells into the calf of the leg and testing for circulatory improvement. A treatment will given at random to two groups and will be injection into the calf muscle with ALD-301 (specially processed stem and progenitor cells) from the patient's own bone marrow, or with cells processed by more routine that minimally purifies the cells. The study goal is to see if the ALD-301 cells are more effective in generating new small blood vessels to improve the circulation to the affected leg.
Conditions Studied
Interventions
- PROCEDURE ALDH-br bone marrow cells vs. mononuclear bone marrow cells
Study Locations (5)
Alabama
- Cardiology PC - Birmingham
Georgia
- Saint Joseph's Research Institute - Atlanta
Indiana
- University of Indiana at Indianapolis - Indianapolis
North Carolina
- Duke University Medical Center - Durham
Texas
- Texas Heart Institute, Stem Cell Center, 6770 Bertner, St Luke's Episcopal Hospital - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2006-10 |
| Est. Completion | 2008-12 |
| Phase | Phase 1 |
What the finished NCT00392509 record still lists
NCT00392509 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 4,206-participant average among 79 other Peripheral Arterial Disease trials with a reported enrollment target (100% lower).
The record links to 3 conditions, with Peripheral Arterial Disease appearing as the primary indexed condition, and to 1 intervention - of which ALDH-br bone marrow cells vs. mononuclear bone marrow cells is the first listed.
NCT00392509 lists 5 locations in 5 states (Alabama, Georgia, Indiana).
Frequently Asked Questions
What is clinical trial NCT00392509 about?
NCT00392509 is a clinical study titled "ALD-301 for Critical Limb Ischemia, Randomized Trial". This study will treat patients with such severe lower leg ischemia or vascular compromise that they have pain at rest. The goal is to compare treatment of the patient's painful disorder by injecting cells into the calf of the leg and testing for circulatory improvement. A treatment will given at ran...
What is the current status of trial NCT00392509?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2006-10. Estimated completion is 2008-12.
What conditions does trial NCT00392509 study?
This clinical trial studies the following conditions: Peripheral Arterial Disease, Peripheral Vascular Disease, Critical Limb Ischemia.
What interventions are being tested in trial NCT00392509?
The interventions under investigation include: ALDH-br bone marrow cells vs. mononuclear bone marrow cells (PROCEDURE).
Who is sponsoring clinical trial NCT00392509?
This trial is sponsored by Aldagen, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00392509 being conducted?
This trial has 5 study locations across Alabama, Georgia, Indiana, North Carolina, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Peripheral Arterial Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00392509's enrollment target sits among peer trials
20 66th of 79 higher than 12 of 79 other Peripheral Arterial Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Peripheral Arterial Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Effects of Carnosine In Patients With Peripheral Arterial Disease Patients
RECRUITING · Phase 1
-
Carnosine for Peripheral Arterial Disease Patients
RECRUITING · Phase 1
-
BGC101 (EnEPC) Autologous Cell Therapy From Patient's Own Blood for Treatment of Critical Limb Ischemia (CLI)
ACTIVE NOT RECRUITING · Phase 1
-
Study of Human Placenta-derived Cells (PDA002) to Evaluate the Safety and Effectiveness in Subjects With PAD and DFU
COMPLETED · Phase 1
-
Natural Vascular Scaffold (NVS) Therapy for Treatment of Atherosclerotic Lesions (Activate I)
COMPLETED · Phase 1
-
A Clinical and Histological Analysis of Mesenchymal Stem Cells in Amputation
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia